JBIO (STOCKS)
Jade Biosciences, Inc. Common Stock
$18.460000
+0.570000 (+3.19%)
Prev close: $17.890000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Tom Frohlich
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $910.38M
- Employees
- 55
- P/E (TTM)
- -3.39
- P/B (TTM)
- 2.65
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Recent News
No recent news found for this ticker.
Financial Statements
| Revenues | $0.00 |
| Nonoperating Income/Loss | -$13.81M |
| Operating Expenses | $113.54M |
| Research and Development | $93.12M |
| Other Operating Expenses | $20.42M |
| Operating Income/Loss | -$113.54M |
| Income/Loss From Continuing Operations After Tax | -$127.41M |
| Income/Loss From Continuing Operations Before Tax | -$127.35M |
| Income Tax Expense/Benefit | $58.00K |
| Income Tax Expense/Benefit, Current | $102.00K |
| Income Tax Expense/Benefit, Deferred | -$44.00K |
| Net Income/Loss | -$127.41M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$127.41M |
| Net Income/Loss Available To Common Stockholders, Basic | -$100.14M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | -$27.27M |
| Preferred Stock Dividends And Other Adjustments | -$27.27M |
| Basic Earnings Per Share | -$3.19 |
| Diluted Earnings Per Share | -$3.19 |
| Basic Average Shares | 31,359,958 |
| Diluted Average Shares | 31,359,958 |
| Assets | $349.78M |
| Current Assets | $348.82M |
| Noncurrent Assets | $965.00K |
| Liabilities | $17.26M |
| Current Liabilities | $16.54M |
| Accounts Payable | $2.15M |
| Wages | $4.73M |
| Other Current Liabilities | $9.66M |
| Noncurrent Liabilities | $724.00K |
| Equity | $332.52M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $332.52M |
| Liabilities And Equity | $349.78M |
| Net Cash Flow From Operating Activities | -$94.69M |
| Net Cash Flow From Operating Activities, Continuing | -$94.69M |
| Net Cash Flow From Investing Activities | -$247.01M |
| Net Cash Flow From Investing Activities, Continuing | -$247.01M |
| Net Cash Flow From Financing Activities | $360.77M |
| Net Cash Flow From Financing Activities, Continuing | $360.77M |
| Net Cash Flow | $19.07M |
| Net Cash Flow, Continuing | $19.07M |
| Comprehensive Income/Loss | -$127.28M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$127.28M |
| Other Comprehensive Income/Loss | $129.00K |